vs
Side-by-side financial comparison of Northfield Bancorp, Inc. (NFBK) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
Northfield Bancorp, Inc. is the larger business by last-quarter revenue ($41.3M vs $34.1M, roughly 1.2× ZEVRA THERAPEUTICS, INC.). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs 12.7%). Northfield Bancorp, Inc. produced more free cash flow last quarter ($52.5M vs $5.5M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 15.0%).
Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
NFBK vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $41.3M | $34.1M |
| Net Profit | $-27.4M | — |
| Gross Margin | — | — |
| Operating Margin | -1263.3% | 27.3% |
| Net Margin | -1545.5% | — |
| Revenue YoY | 12.7% | 183.4% |
| Net Profit YoY | -343.6% | — |
| EPS (diluted) | $-0.68 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $41.3M | $34.1M | ||
| Q3 25 | $39.2M | $26.1M | ||
| Q2 25 | $38.9M | $25.9M | ||
| Q1 25 | $34.8M | $20.4M | ||
| Q4 24 | $36.7M | $12.0M | ||
| Q3 24 | $31.8M | $3.7M | ||
| Q2 24 | $31.5M | $4.4M | ||
| Q1 24 | $31.3M | $3.4M |
| Q4 25 | $-27.4M | — | ||
| Q3 25 | $10.8M | $-544.0K | ||
| Q2 25 | $9.6M | $74.7M | ||
| Q1 25 | $7.9M | $-3.1M | ||
| Q4 24 | $11.3M | — | ||
| Q3 24 | $6.5M | $-33.2M | ||
| Q2 24 | $6.0M | $-19.9M | ||
| Q1 24 | $6.2M | $-16.6M |
| Q4 25 | -1263.3% | 27.3% | ||
| Q3 25 | 37.7% | 15.9% | ||
| Q2 25 | 35.6% | -274.5% | ||
| Q1 25 | 31.0% | -26.3% | ||
| Q4 24 | 38.0% | -128.0% | ||
| Q3 24 | 27.9% | -739.0% | ||
| Q2 24 | 29.1% | -534.8% | ||
| Q1 24 | 27.2% | -598.1% |
| Q4 25 | -1545.5% | — | ||
| Q3 25 | 27.4% | -2.1% | ||
| Q2 25 | 24.6% | 288.7% | ||
| Q1 25 | 22.6% | -15.2% | ||
| Q4 24 | 30.7% | — | ||
| Q3 24 | 20.5% | -899.2% | ||
| Q2 24 | 18.9% | -447.9% | ||
| Q1 24 | 19.9% | -485.3% |
| Q4 25 | $-0.68 | — | ||
| Q3 25 | $0.27 | $-0.01 | ||
| Q2 25 | $0.24 | $1.21 | ||
| Q1 25 | $0.19 | — | ||
| Q4 24 | $0.27 | — | ||
| Q3 24 | $0.16 | $-0.69 | ||
| Q2 24 | $0.14 | $-0.48 | ||
| Q1 24 | $0.15 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $164.0M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $690.1M | $154.7M |
| Total Assets | $5.8B | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $164.0M | $62.4M | ||
| Q3 25 | $131.7M | $54.4M | ||
| Q2 25 | $97.6M | $47.7M | ||
| Q1 25 | $101.7M | $37.3M | ||
| Q4 24 | $167.7M | $33.8M | ||
| Q3 24 | $232.9M | $54.0M | ||
| Q2 24 | $153.5M | $39.3M | ||
| Q1 24 | $238.8M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | $666.4M | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $690.1M | $154.7M | ||
| Q3 25 | $719.6M | $133.2M | ||
| Q2 25 | $710.3M | $117.2M | ||
| Q1 25 | $711.1M | $41.0M | ||
| Q4 24 | $704.7M | $39.7M | ||
| Q3 24 | $699.6M | $69.8M | ||
| Q2 24 | $693.0M | $32.5M | ||
| Q1 24 | $698.4M | $48.8M |
| Q4 25 | $5.8B | $284.7M | ||
| Q3 25 | $5.7B | $270.1M | ||
| Q2 25 | $5.7B | $256.3M | ||
| Q1 25 | $5.7B | $172.7M | ||
| Q4 24 | $5.7B | $178.1M | ||
| Q3 24 | $5.7B | $191.6M | ||
| Q2 24 | $5.7B | $144.4M | ||
| Q1 24 | $5.9B | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.95× | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.7M | $5.5M |
| Free Cash FlowOCF − Capex | $52.5M | $5.5M |
| FCF MarginFCF / Revenue | 127.1% | 16.1% |
| Capex IntensityCapex / Revenue | 2.8% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $89.2M | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.7M | $5.5M | ||
| Q3 25 | $13.9M | $4.7M | ||
| Q2 25 | $14.1M | $-3.6M | ||
| Q1 25 | $9.4M | $-8.2M | ||
| Q4 24 | $31.1M | $-16.3M | ||
| Q3 24 | $14.0M | $-18.1M | ||
| Q2 24 | $6.9M | $-19.1M | ||
| Q1 24 | $4.2M | $-16.2M |
| Q4 25 | $52.5M | $5.5M | ||
| Q3 25 | $13.6M | $4.2M | ||
| Q2 25 | $13.9M | $-3.8M | ||
| Q1 25 | $9.2M | $-8.3M | ||
| Q4 24 | $30.0M | — | ||
| Q3 24 | $13.7M | — | ||
| Q2 24 | $6.7M | — | ||
| Q1 24 | $3.8M | — |
| Q4 25 | 127.1% | 16.1% | ||
| Q3 25 | 34.6% | 15.9% | ||
| Q2 25 | 35.7% | -14.7% | ||
| Q1 25 | 26.3% | -40.8% | ||
| Q4 24 | 81.6% | — | ||
| Q3 24 | 43.2% | — | ||
| Q2 24 | 21.1% | — | ||
| Q1 24 | 12.1% | — |
| Q4 25 | 2.8% | 0.1% | ||
| Q3 25 | 0.8% | 2.1% | ||
| Q2 25 | 0.6% | 0.8% | ||
| Q1 25 | 0.7% | 0.5% | ||
| Q4 24 | 3.1% | 0.0% | ||
| Q3 24 | 0.7% | 0.0% | ||
| Q2 24 | 0.8% | 0.0% | ||
| Q1 24 | 1.4% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | 1.48× | -0.05× | ||
| Q1 25 | 1.20× | — | ||
| Q4 24 | 2.76× | — | ||
| Q3 24 | 2.14× | — | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NFBK
Segment breakdown not available.
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
